Optiflow™
Flow Matters

Evidence continues to published almost weekly demonstrating the contribution of Nasal High Flow to improved patient care and outcomes.
Flow Matters is designed to keep you up to date with this emerging clinical evidence and practice guidelines.

Subscribe

Publications by year
(pubmed.com)

Search term "nasal high flow"
(as of 25th Jan 2021)

Registered clinical trials
(clinicaltrials.gov)

Search term "nasal high flow"
(as of 25th Jan 2021)

Clinical practice guideline

 
(Rochwerg et al. 2020. Intensive Care Med.)
This clinical practice guideline (Rochwerg et al. 2020. Intensive Care Med.) synthesizes current best evidence into four recommendations for NHF in adult patients.

Acute hypoxemic
respiratory failure

For primary respiratory support compared to COT.
Recommendation made with moderate certainty.


 

 Strong
Recommendation 

Post-operative
 
For primary respiratory support compared to COT in high risk and/or obese patients following cardiac or thoracic surgery.
Recommendation made with moderate certainty.


 Conditional Recommendation 
Peri-intubation
 
For pre-oxygenation prior to in-ICU intubation no recommendation is made compared to COT.
NHF during intubation should be continued for patients who are already receiving NHF.*

 Continue NHF* 
Post-extubation
respiratory failure
 
For post-extubation respiratory support compared to COT following extubation.
Recommendation made with moderate certainty.



 Conditional Recommendation 

*For patients who are already receiving NHF, guideline authors suggest continuing NHF during intubation (conditional recommendation, moderate certainty).

Flow Matters

In this edition of Flow Matters we outline the recommendations, discuss the evidence-practice gap, the economics of Nasal High Flow.

 

PDF Read Now

SHARE THIS EDITION

LinkedIn  Twitter

 


 		 What systems and settings are
used in NHF research?
Surveys of the studies comprising
the body of NHF evidence found
the majority used F&P Optiflow
systems and flow settings between
45 and 60L/min.		 PDF Read online

SHARE THIS EDITION

LinkedIn Twitter






 
 

 


 		 NHF is recognized by the
WHO for treatment of patients with
COVID-19.
Read about this and research
related to airborne transmission.		 PDF Read online

SHARE THIS EDITION

LinkedIn Twitter






 
 

 


 		 A bedside tool for
monitoring patients on NHF.
The validated ROX index uses just 3
data points to provide an indicator
of outcomes in adults with AHRF
receiving NHF therapy.


AUTHOR:
Stanislav Taktov, M.D., Ph.D.		 PDF Read online

SHARE THIS EDITION

LinkedIn Twitter






 

Subscribe to Flow Matters 

If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.
Enter security code
 Security code

The outbreak of COVID-19 has impacted healthcare organizations around the world

A resource center has been created to provide affected hospitals and healthcare professionals with information they may need to treat patients when using Fisher & Paykel Healthcare products.
 

View resource center